• Development of cell-based screening systems for target identification and validation purposes
• Target validation (siRNA approaches, stable and transient overexpression of normal and mutant proteins in differrent mammalian cell lines)
• Molecular cloning and expression of therapeutic targets for structural studies:
  • Bacterial-, baculo-, mammalian cell expression
  • Cell-free expression in NMR-active form
• Lead docking in silico, validation by mutagenized or modified proteins
• PCR kit development, validation and contract manufacturing under ISO9002/CE.